CureGene announced the closing of near USD 47 million in Series C financing in the first quarter of 2026. This round was led by Walvax Biotechnology, with continued participation from Taikun Fund under Tailong Capital, and joined by several prominent investors including Qianhai Ark Fund and Shenzhen Credit Venture Capital. The proceeds will be used primarily to accelerate global clinical development of the company’s core pipeline assets. The strong backing from both industrial and financial investors marks a significant acceleration in CureGene's growth trajectory. 

Founded in 2018 in Zhangjiang, Shanghai, CureGene has built two globally leading technology platforms: the CureGene-X1 “Aosheng” mRNA Therapeutic Platform and the A-proX™ “Puyu” Prodrug Platform, dedicated to developing innovative drugs with global competitiveness. The company's pipeline includes multiple candidates with wholly owned intellectual property and substantial market potential. The core team, drawn from world-renowned multinational pharmaceutical companies, brings deep expertise in innovative drug R&D, clinical operations, and commercialization across multiple therapeutic areas including cardiovascular and cerebrovascular diseases, metabolism, and antiviral therapies. 

Figure 1: Current pipeline progress

CureGene's lead product, Evategrel (CG-0255), is a global best-in-class, next-generation P2Y12 receptor inhibitor available in both intravenous and oral formulations. Utilizing a novel thiol-hydrolyzing prodrug design, it achieves rapid onset of action (less than 15 minutes for injection, less than 30 minutes for oral administration) and completely overcomes the "clopidogrel resistance" issue, which affects approximately 58% of the Chinese population.

Clinical data demonstrate superior antiplatelet efficacy, with a 2 mg dose achieving the same pharmacodynamic effect as 300 mg of clopidogrel, with a favorable safety profile, minimized inter-patient variability, and low risk of drug-drug interactions. The injectable formulation addresses a critical unmet need in stroke treatment globally, while the oral formulation offers a solution to key limitations of current therapies. Evategrel is currently advancing through registrational clinical studies in the United States and a Phase II clinical study in China.

Beyond its lead asset, CureGene has achieved significant progress across several other innovative drug candidates with global IP:

CG-0416 (for obesity and metabolic liver disease): The next-generation, highly selective, liver-targeting THR-β agonist has successfully entered Phase I clinical development. Also developed on the “Puyu” prodrug platform, CG-0416 offers a differentiated mechanism of action. It does not rely on central appetite suppression; instead, it efficiently reduces liver fat and body weight while markedly preserving muscle mass. This positions CG-0416 as a potential new oral option for "high-quality weight loss." in patients with obesity and metabolic diseases.

CG-1999 (for functional cure of hepatitis B): Leveraging the "Aosheng" mRNA platform, CureGene has developed a therapeutic vaccine aimed at achieving functional cure of hepatitis B.  CG-1999 induces robust, HBV-specific immune responses, leading to effective suppression and clearance of the hepatitis B virus. In animal models, CG-1999 demonstrated a clear synergistic effect when combined with siRNA or ASO, significantly accelerating the reduction of hepatitis B surface antigen (HBsAg) while effectively suppressing viral rebound after treatment discontinuation.

Dr. He Gongxin, Founder and CEO of CureGene, commented, “We are truly grateful for the recognition and support from both new and existing investors. This financing represents a major milestone for CureGene and will greatly accelerate the global clinical development of our core products. We remain committed to addressing major unmet medical needs in cardiovascular, cerebrovascular, and metabolic diseases through foundational innovation, and to bringing better treatment options to patients around the world as soon as possible.”

For more information, please contact: info@curegene.com.cn